Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017
November 01 2017 - 9:19AM
Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage
biopharmaceutical company, today announced that it will report its
third quarter financial results after the close of the U.S.
financial markets on Wednesday, November 8, 2017. Following the
financial results announcement, members of management will host a
conference call and live audio webcast to discuss the results and
provide a general corporate update. Access to the conference call
can be obtained as follows:
Live access on Wednesday, November 8, 2017
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
Telephone: +1 (877) 280-7291 (domestic) or +1 (707) 287-9361
(international)
Live webcast and replay will be available via the “Events &
Presentations” page of the “News & Events” section of the
Cascadian Therapeutics’ website at www.cascadianrx.com.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical
company dedicated to developing innovative product candidates for
the treatment of cancer. Its lead product candidate, tucatinib, is
an investigational oral, selective small molecule HER2 inhibitor.
Cascadian Therapeutics is conducting a randomized, double-blind
controlled pivotal clinical trial called HER2CLIMB, which is
comparing tucatinib vs. placebo, each in combination with
capecitabine and trastuzumab, in patients with locally advanced or
metastatic HER2-positive breast cancer with and without brain
metastases, who have previously been treated with trastuzumab,
pertuzumab and T-DM1. Additional details on HER2CLIMB can be
found at www.HER2CLIMB.com or www.clinicaltrials.gov. For more
information, please visit www.cascadianrx.com.
Investor and Media Contact:Monique
Greer206-801-2107mgreer@cascadianrx.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Apr 2023 to Apr 2024